• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 15, 2016

View Archived Issues

Bench Press: BioWorld looks at translational medicine

Read More

Financings

Arrowhead Pharmaceuticals Inc., of Pasadena, Calif., said it closed its private offering with investors, including Orbimed, RA Capital Management, Perceptive Advisors, RTW Investments and certain other institutional investors. About 7.63 million shares of common stock were issued at a price of $5.90 apiece. Gross proceeds totaled $45 million. Read More

Appointments & advancements

Fennec Pharmaceuticals Inc., of Research Triangle Park, N.C., appointed Marco Brughera to its board. Read More

Other news to note

Endo International plc, of Dublin, said based on an Aug. 11 discussion with the FDA, it is withdrawing its supplemental NDA relating to specific abuse-deterrent labeling for Opana ER (extended-release oxymorphone) without prejudice to re-filing. The company said it plans to continue collecting and analyzing epidemiological data. Opana ER is an opioid agonist approved for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatment options are inadequate. Read More

Regulatory front

The FDA completed a comprehensive review of the safety information relevant to the investigational small-molecule inhibitor of fatty acid amide hydrolase (FAAH) from Bial-Portela & Ca. SA, of Sao Mamede do Coronado, Portugal, linked to one death and five hospitalizations of volunteer subjects in a phase I trial at a France hospital early this year. Read More

In the clinic

Acacia Pharma Group plc, of Cambridge, U.K., reported results from a pivotal phase III study testing Baremsis (amisulpride injection, formerly APD421) for the treatment of established postoperative nausea and vomiting (PONV), which the firm said further support efficacy previously shown in PONV alone, and in combination with standard antiemetics in phase III prophylaxis studies. The study compared two doses of Baremsis, a dopamine D2/D3 antagonist antiemetic, against placebo in patients with established nausea and/or vomiting after surgery, who had not previously received any prophylactic antiemetics. ) Read More

Ahem: SEAMLESS aside, Cyclacel well enough as investors knit brows over odds in AML study

Even if Wall Street scratches off the soon-to-report, longshot phase III SEAMLESS trial in acute myeloid leukemia (AML), Cyclacel Pharmaceuticals Inc. may have value aplenty in an early stage pair of other clinical programs. But home-run hopes die hard and biotech is full of surprises – such as Vyxeos, the late-stage AML winner in March for Celator Pharmaceuticals Inc. Read More

Up-and-coming Tapimmune seeks 'more eyes' on I-O assets with uplisting

Immunotherapy developer Tapimmune Inc., which began life back in 2000 as Genemax Corp., quietly inked a series of deals and kept its head down during the formative years of the immuno-oncology (I-O) field. Read More

Compound, target for fighting three tropical diseases

A single compound was able to rid mice of three separate parasitic infections, opening the possibility of developing a relatively broad-spectrum approach against the three, which are collectively known as kinetoplastids. Read More

The challenges that are keeping biotech execs awake at night

Building a successful biotechnology company requires that its executives make decisions to help navigate a smooth path around barriers that could easily hinder progress. There is no doubt that running a biopharma company involves plenty of risks in an ever-changing financial and regulatory landscape. Read More

Oricula's otoprotective drug could bring back aminoglycoside use

While its name obviously reflects its work in the field of hearing loss, Oricula Therapeutics Inc.'s biggest impact could actually be in the antibiotics space, focusing its efforts amid the recent global call to action on tackling antimicrobial resistance. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe